Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT05582395Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoints: Kansas City Cardiomyopathy Questionnaire-23 Clinical Summary Score at 48 weeks and Peak Oxygen Consumption at 48 weeks. Started Dec 2022; status: terminated.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05582395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582395.